News – AcelaBio

AcelaBio (US) Inc. obtains accreditation from the College of American Pathologists (CAP)

San Diego, CA, USA, Release: September 15, 2022 – AcelaBio (US) Inc., a contract research organization delivering histopathology and precision medicine laboratory services for global clinical trials, achieved its accreditation by the College of American Pathologists (CAP). CAP accreditation indicates that the laboratory meets stringent requirements of quality, accuracy, and consistency of test results to… Continue reading AcelaBio (US) Inc. obtains accreditation from the College of American Pathologists (CAP)

AcelaBio – Employee Spotlight presents, Jen Simmonds

At AcelaBio, our employees come first. We engage inspired and talented individuals who help us shape the future of delivering reliable, high-quality clinical research services. Today, we are highlighting one of our employees, Jen Simmonds, Histotechnologist. We asked Jen some questions and to take us through a day in her role at AcelaBio! How long have… Continue reading AcelaBio – Employee Spotlight presents, Jen Simmonds

Development and Validation of a Digital Analysis
Method

An image analysis method was developed to quantify CD3+ T cells in Crohn’s disease biopsies. Its accuracy, reliability, and reproducibility were validated using manual assessment and 3 digital pathology software packages, and these tools can further enhance pathology review. To read this study, please visit: https://lnkd.in/gDJCGvAr Congratulations to Pavine Lefevre, Leonardo Guizzetti, Tanja van Viegen, Stefanie M.,… Continue reading Development and Validation of a Digital Analysis
Method

AcelaBio – Proudly Announcing The Grand Opening

AcelaBio is proud to announce the official grand opening of our new lab space, located in San Diego California. We are excited to allow our colleagues the opportunity to visit and learn more about our services. For more information, please contact us at info@acelabio.com

AcelaBio Will Be Attending Digestive Disease Week In San Diego

Meet with members of our AcelaBio team at DDW 2022, and learn more about our new state-of-the-art laboratory based in San Diego, California. To set up a meeting with us, please contact us at info@acelabio.com or visit booth 1149.

Alimentiv Health Trust Launches AcelaBio (US) Inc. Today

London, ON, CANADA, Release: April 14, 2021 – Alimentiv Health Trust, the parent company of Alimentiv, Inc. (formerly Robarts Clinical Trials), a specialized global gastrointestinal (GI) contract research organization (CRO), and McDougall Scientific Ltd., a niche CRO, announced today the launch of AcelaBio, a commercial state-of-the-art research laboratory delivering histopathology and precision medicine services for… Continue reading Alimentiv Health Trust Launches AcelaBio (US) Inc. Today

Implementation of Histopathology in GI Clinical Trials

Join our expert panel where they will discuss inflammatory bowel disease and NASH, two therapeutic areas that histopathology uses to determine eligibility and/or primary outcome measures. Our four experts will provide presentations on topics including Histopathology as a treatment target in IBD: Aspiration or Reality? Measuring histopathology in IBD trials Histopathology as a treatment target… Continue reading Implementation of Histopathology in GI Clinical Trials

Precision Medicine in IBD – From Clinical Research to Clinical Practice

Hear what the experts had to say in this recent live stream event with Dr. Séverine Vermeire, Dr. Deanna Nguyen, and Dr. Niels Vande Casteele presenting Precision Medicine in IBD Clinical Research. Dr. Vermeire presents how a translational medicine program successfully supported the development of a new compound – a gut-selective pan-Janus kinase inhibitor. Dr.… Continue reading Precision Medicine in IBD – From Clinical Research to Clinical Practice